

Plants for Problem Solution: Therapeutics

Shah Murad^{*1}, Asia Firdous², Humaira Mahmood³, Seema Shah Murad⁴ and Adnan Shafique⁵

¹Professor of Therapeutics at Islamabad Medical and Dental College, Islamabad, Pakistan

²Asia Firdous, AP Pharmacology at Lahore Medical and Dental College, Lahore, Pakistan

³Humaira Mahmood, Coordinator Research at Armed Forces Post Graduate Medical Institute, National University of Medicinal Sciences, Rawalpindi, Pakistan

⁴Seema Shah Murad, Gynecologist at National Medical Centre, Karachi, Pakistan

⁵Adnan Shafique, Consultant Pharmacist at MCC Pharmacy, Islamabad, Pakistan

Abstract

Lipoprotein(a) is a type of lipoprotein/cholesterol and high levels increase your risk for atherosclerosis (buildup of fatty deposits in the wall of the artery, also called atherosclerotic cardiovascular disease or CVD) including coronary heart disease (blockages in your heart arteries) or heart attack, peripheral vascular disease (PAD, blockages in the leg arteries), aortic stenosis (damage to the aortic valve of the heart), thrombosis (blood clots) and stroke (blockages in the neck arteries). In children, a high level of Lp(a) is a leading risk factor for strokes but strokes are very rare in any child, even those with a high level of Lp(a). Analysis of the lipid content in the oxidatively modified LDL from hyperlipidemic patients revealed that the level of lysophosphatidylcholine was greatly elevated, and the high level of the lysolipid was shown to impair the endothelium-dependent relaxation of the blood vessels. In allopathy blood lipid levels are normalized by statins, fibrates, niacin and bile acid binding resins (BABRs). All of these allopathy related drugs have low compliance ranges from mild compliance due to metallic taste of BABRs to severe side effects like rhabdomyolysis by fibrates and statins. Cardiovascular diseases are leading cause of death in western and eastern countries of the world. Hyperlipidemia is one of the strong risk fractions for heart diseases. To evaluate hypolipidemic drugs efficacy, the study was conducted at Ghurki trust teaching hospital, Lahore Pakistan from January 2018 to August 2018. 1980, hyperlipidemic patients were selected from cardiology and medical wards of the hospital. They were divided in three groups, one at placebo therapy, another on Kalonji and third one on Vitamin B3. After one and half month, significant changes (p value ranging from <0.05 to <0.001) were observed in their LDL and HDL-cholesterol. Conclusion of the study was to recommend use of herbal medicine and vitamin B3 for prevention of any heart diseases with good patient compliance.

Introduction

Lipoprotein (a), is a particle in your blood which carries cholesterol, fats and proteins. The amount your body makes is inherited from one or both parents and is determined by the genes passed on from your parent(s) when you are born. It does not change very much during your lifetime except if you are women, levels increase as the natural estrogen level declines with menopause. Diet and exercise seems to have little to no impact on the lipoprotein (a) level.

Due to low compliance and adverse effects of conventionally used hypolipidemic agents, herbal medicines are going to be famous among Physicians, and Cardiologists. Medicinal herbs like Curcuma Longa, Fenugreek, and Lemon contents are being used as mild to moderate hypolipidemic agents. Curcuma Longa commonly known as Haldi in India and Pakistan is used to lower plasma lipids, in view of their contents. It contains Curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin), turmerone, atlantone, zingiberene, proteins, and resins. Coronary artery disease (CAD) occurs when the inside (the lumen) of one or more coronary arteries narrows, limiting the flow of oxygen-rich blood to surrounding heart muscle tissue. Atherosclerosis is the process that causes the artery wall to get thick and stiff. It can lead to complete blockage of the artery, which can cause a heart attack [1]. The disease process begins when LDL deposits cholesterol in the artery wall. The body has an immune response to protect itself and sends white blood cells called macrophages to engulf the invading cholesterol in the artery wall. When the macrophages are full of cholesterol, they are called foam cells because of their appearance. As more foam cells collect in the artery wall, a fatty streak develops between the intima and the media. If the process is not stopped, the fatty streak becomes a plaque, which pushes the intima into the lumen, narrowing the blood flow [2-6]. With few exceptions, low HDL is an independent risk factor for CAD in case-control and

prospective observational studies [7]. In contrast, high HDL levels are associated with longevity and are protective against the development of atherosclerotic disease [8]. In the Framingham Study, risk for CAD increases sharply as HDL levels fall progressively below 40 mg/dL [9-10]. In the Quebec Cardiovascular Study, for every 10% reduction in HDL, risk for CAD increased 13%. [2] Many clinicians believe that low HDL is associated with increased CAD risk because it is a marker for hypertriglyceridemia and elevated remnant particle concentrations. The Prospective Cardiovascular Münster Study, however, demonstrated that the increased risk associated with low HDL is independent of serum triglyceride levels [11]. There is considerable controversy about whether one HDL subfraction is more antiatherogenic than others. At the present time, the preponderance of evidence favors increasing total HDL mass, rather than any one subfraction of this lipoprotein [12].

Material and Method

The study was conducted at Ghurki trust teaching hospital, Lahore Pakistan from January 2018 to August 2018. 90 patients were selected for study. Consent was taken from all participants. An inclusion

***Corresponding author:** Shah Murad, Department of Therapeutics and Pharmacology, Islamabad Medical and Dental College, Islamabad, Pakistan, E-mail: shahmurad65@imdc.edu.pk

Received: 14-Apr-2022, Manuscript No. wjpt-22-60804; **Editor assigned:** 16-Apr-2022, PreQC No. wjpt-22-60804 (PQ); **Reviewed:** 30-Apr-2022, QC No. wjpt-22-60804; **Revised:** 05-May-2022, Manuscript No. wjpt-22-60804 (R); **Published:** 12-May-2022, DOI: 10.4172/wjpt.1000158

Citation: Murad S, Firdous A, Mahmood H, Murad SS, Shafique A (2022) Plants for Problem Solution: Therapeutics. World J Pharmacol Toxicol 5: 158.

Copyright: © 2022 Murad S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

criterion was primary and secondary hyperlipidemic patients. An exclusion criterion was patients suffering from any kidney, liver and thyroid related disease. Name, age, gender, occupation, residential address, phone/contact number, previous medical history, disease in family history, drug history were recorded in specific Performa. Three groups I, II, and III were made (30 patients in each group). Group-I was allocated for placebo, to take placebo capsule once daily, after breakfast for six weeks. Group-II was advised to take 2 tea spoons of kalonji after breakfast for the period of six weeks. Group-III was on Niacin 2 grams in divided doses, after breakfast, lunch and dinner for 6 weeks. Their base line LDL-cholesterol and HDL-cholesterol level was estimated at the start of research work. Their serum was taken at follow up visits, fortnightly for lipid profile. Data were expressed as the mean \pm SD and 't' test was applied to determine statistical difference in results. A p-value $>$ 0.05 was considered as non-significance and P-value $<$ 0.001 was considered as highly significant change in the differences. Serum LDL-cholesterol was calculated by formula (LDL-Cholesterol= Total Cholesterol-(Triglycerides/5 +HDL-Cholesterol). Serum HDL-cholesterol was determined by using kit Cat. # 3022899 by Eli Tech Diagnostic, France.

Data Inference and Results

Numerical values and results of all parameters of participated patients were analyzed biostatistically. In placebo group, LDL-cholesterol decreased from 189.15 ± 3.90 mg/dl to 186.75 ± 2.08 mg/dl, change in the parameter is 2.40 mg/dl. This difference in pretreatment and post treatment value is non-significant, i.e., P-value $>$ 0.05. HDL-cholesterol in placebo group increased from 36.11 ± 2.11 mg/dl to 37.17 ± 1.51 mg/dl. The difference in parameter was 1.06mg/dl. Statistically this change in parameter was non-significant i.e., P-value $>$ 0.05. In Nigella sativa group, out of 30 hyperlipidemic patients, 27 patients completed over all study period. LDL-cholesterol in this group decreased from 202.45 ± 1.54 mg/dl to 189.52 ± 2.21 mg/dl. The difference in pretreatment and post-treatment mean values is 12.93 mg/dl. Statistically this change in two mean values is highly significant, with p-value $<$ 0.001. HDL- cholesterol in this group increased from 38.81 ± 3.90 to 42.19 ± 3.32 mg/dl. Change in two mean values was 3.38 mg/dl. Statistically this change is significant, with probability value $<$ 0.01. In group III, 28 patients completed the research. LDL-cholesterol in this group decreased from 212.65 ± 2.32 to 185.61 ± 3.43 mg/dl in 6 weeks treatment. Change in pre and post treatment mean values is 27.04 mg/dl. Statistically this change is highly significant, i.e., P-value $<$ 0.001. HDL-cholesterol increased from 39.19 ± 2.01 to 43.00 ± 3.07 mg/dl in 6 weeks. Change in two parallel values is 3.49 mg/dl, which is significant with P-value $<$ 0.01 (Table 1).

Discussion

Cholesterol is produced naturally in your liver because every cell in your body uses it. Similar to triglycerides, cholesterol is also found

in fatty foods like eggs, red meat, and cheese. Hyperlipidemia is more commonly known as high cholesterol. Although high cholesterol can be inherited, it's more often the result of unhealthy lifestyle choices. Treatment with three weeks, Kalonji decreased LDL-cholesterol 12.93 mg/dl by six weeks of treatment. HDL-cholesterol increased 3.38 mg/dl by taking this drug for six weeks. The changes in both parameters were significant.

In placebo group, LDL-C reduction was 2.40 mg/dl and increase in HDL-C was 1.06 mg/dl with P-value $>$ 0.05, which proves non-significant change in results. These results match with Akhondian et al. [13] who did prove that Nigella sativa is very effective hypolipidemic drug. He tested the drug on 120 hyperlipidemic and diabetic patients by using Nigella sativa for one month. Their results were highly significant when compared with placebo-controlled group. Our results also match with results of Gillani AH et al. [14] who proved LDL-Cholesterol reduction from 201.61 ± 3.11 mg/dl to 187.16 ± 2.10 mg/dl in 40 hyperlipidemic patients. Their HDL-C increase was 3.98 mg/dl which also matches with our results. Results of our study are in contrast with results of research work conducted by AH BH and Blunden G [15]. They explained that some active ingredients of Nigella sativa are hypolipidemic but their hypolipidemic effects are very narrow spectrum. Their results showed only 2.11 mg/dl change in LDL-C and 0.92 mg/dl increase in HDL-C of 38 rats. Difference in results may be genetic variants of human and rats. Brown BG et al. [16] also described phenomenon of genetic variation in pharmacological effects of Nigella sativa. Burits M and Bucar F [17] have also mentioned wide variety effects of Nigella sativa with different genetic make ups. Our results also match with results of research work of Dehkordi FR, Kamkhah AF [18] and El-Dakhakhany M [19]. Same mechanism of action of drug Nigella sativa is described by El-Din K et al. [20]. In our research reduced LDL-Cholesterol from 212.65 ± 1.19 mg/dl to 185.61 ± 1.65 mg/dl in six weeks. This reduction in LDL-C was 27.04 mg/dl, which is highly significant change, when analyzed statistically. These results match with results n of research work conducted by Afilalo J et al. [21] who proved almost same change in LDL-C in 32 hyperlipidemic patients who were cases of secondary hyperlipidemia and used Niacin 2 grams daily for 2 months. Their LDL-C reduction was 25.55 mg/dl. Their HDL-C increase was 6.65 mg/dl in 2 months. In our results HDL-C increase was 3.81 mg/dl in six weeks use of Niacin. Our results also match with results of research conducted by Whitney EJ et al. [22] who proved 27.77 mg/dl reduction in LDL-C in 19 hyperlipidemic patients. Ginsberg HN et al. [23] also support our results, as they proved 4.00 mg/dl increase in HDL-C when 2 grams of Niacin was used in 34 hyperlipidemic patients for 6 weeks. Our results do not match with results of research conducted by Boden WE et al. [24] who proved that 2.5 grams Niacin decreased 10.99 mg/dl LDL-Cholesterol. HDL-C increase was only 1.11 mg/dl. These differences may be considered due to lack of physical exercise and no restriction of use of lipids in their diet. Taylor AJ et al. [25] used Niacin 1.5 grams in 29 hyperlipidemic

Table 1: LDL, HDL's basic values (pre and after treatment) and their biostatistical significance.

No. of patients	Day- 0 values	Day- 45 values	Change in basic values	Statistical significance
Placebo (30 pts)	LDL-c= 189.15 ± 3.90	LDL= 186.75 ± 2.08	2.4	$>$ 0.05
	HDL-c= 36.11 ± 2.11	HDL= 37.17 ± 1.51	1.06	$>$ 0.05
Kalonji (27 pts)	LDL-c= 202.45 ± 1.54	LDL= 189.52 ± 2.21	12.93	$<$ 0.001
	HDL-c= 38.81 ± 3.90	HDL= 42.19 ± 3.32	3.38	$<$ 0.01
Vit B3 (28 pts)	LDL-c= 212.65 ± 2.32	LDL= 185.61 ± 3.43	27.04	$<$ 0.001
	HDL-c= 39.19 ± 2.01	HDL= 43.00 ± 3.07	3.49	$<$ 0.01

Key: HDL and LDL are measured in mg/dl, n stands for sample size, p-value $>$ 0.05 indicate non-significant, $<$ 0.01 indicate significant and $<$ 0.001 indicate highly significant change in basic values

patients for 3weeks. Patients reduced their LDL-C from 189.88 ± 1.11 mg/dl to 187.87 ± 0.99 mg/dl. Difference in their results and our results is due to less sample size, lesser duration of exposure of patients to drug and small amount of drug given in their patients. Baigent C et al. [26] explained that Niacin inhibits the peripheral mobilization of free fatty acids, which decreases the substrate available for hepatic synthesis of triglycerides and very low-density lipoprotein (VLDL) particles.

References

1. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B (2016) HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. *Atherosclerosis* 153: 263-272.
2. Barter P (2005) The role of HDL-cholesterol in preventing atherosclerotic disease. *Eur Heart J* 7: 4-8.
3. Sang ZC, Wang F, Zhou Q, Li YH, Li YG, et al. (2010) Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. *Chin Med J* 122: 1615-1620.
4. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, et al. (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 104: 1108-1113.
5. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. *Lancet* 380: 572-580.
6. Ridker PM (2003) C-reactive protein: a simple test to help predict risk of heart attack and stroke. *Circulation* 108: e81-e85.
7. Weverling-Rijnsburger AWE, Jonkers IJAM, Exel EV, Gussekloo J, Westendorp RGJ (2003) High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. *Arch Intern Med* 163: 1549-1554.
8. Toth P (2005) The 'good cholesterol': high-density lipoprotein. (2005) *Circulation* 111: e89-e91.
9. Toth PP (2003) Reverse cholesterol transport: high-density lipoprotein's magnificent mile. *Curr Atheroscler Rep* 5: 386-393.
10. Nofer J, Kehrel B, Fobker M, Levkau B, Assmann G, et al. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. *Atherosclerosis* 161: 1-16.
11. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, et al. (2003) Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. *JAMA* 290: 2292-2300.
12. Haffner SM, American Diabetes Association (2003) Management of dyslipidemia in adults with diabetes. *Diabetes Care* 26: S83-S86.
13. Akhondian J, Parsa A, Rakhshande H (2007) The effect of *Nigella sativa* L. (black cumin seed) on intractable pediatric seizures. *Med Sci Monit* 13: 555-559.
14. Gilani AH, Jabeen Q, Khan MAU (2004) A review of medicinal uses and pharmacological activities of *Nigella sativa*. *Pak J Biol Sci* 7: 441-451.
15. Ali BH, Blunden G (2003) Pharmacological and toxicological properties of *Nigella sativa*. *Phytother Res* 17: 299-305.
16. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 345: 1583-1592.
17. Burits M, Bucar F (2000) Antioxidant activity of *Nigella sativa* essential oil. *Phytother Res* 14: 323-328.
18. Dehkordi FR, Kamkha AF (2008) Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. *Fundam Clin Pharmacol* 22: 447-452.
19. EL-Dakhkhany M (1982) Some pharmacological properties of some constituents of *nigella sativa* seeds: The carbonyl fraction of essential oil. In: *Proceedings of the 2nd International conference on Islamic medicine*. Kuwait: *Studies in Islamic medicine and advantages of herbal treatment* 426-431.
20. El-Tahir K, Bakeet DM (2006) The black seed *Nigella sativa* Linnaeus- a mine for multi cures: A plea for urgent clinical evaluation of its volatile oil. *J Taibah Univ Medical Sci* 1: 1-19.
21. Afilalo J, Majdan AA, Eisenberg MJ (2007) Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. *Heart* 93: 914-921.
22. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, et al. (2005) A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. *Ann Intern Med* 142: 95-104.
23. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 362: 1563-1574.
24. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Nickens DP, et al. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 365: 2255-2267.
25. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2004) Arterial biology for the investigation of the treatment effects of reducing cholesterol (arbiter) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation* 110: 3512-3517.
26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 366: 1267-1278.